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Abstract
Purpose The p62, also called sequestosome 1 (SQSTM1),
plays a crucial role in tumor necrosis factor (TNF)-induced
optic nerve degeneration. Brimonidine has been shown to
have protective effects on retinal ganglion cell bodies, al-
though its role in their axons remains to be examined. We
determined whether brimonidine modulates axonal loss in-
duced by TNF and affects the expression of p62 in the optic
nerve.
Methods Experiments were performed on adult male Wistar
rats that received an intravitreal injection of 10 ng TNF alone
or simultaneous injection of TNF and 2, 20, or 200 pmol of
brimonidine tartrate. The expression of p62 in the optic nerve
was examined by immunoblot analysis. The effects of
brimonidine on axons were evaluated by counting axon num-
bers 2 weeks after intravitreal injection.
Results Intravitreal injection of brimonidine exerted substan-
tial axonal protection against TNF-induced optic nerve degen-
eration. Immunoblot analysis showed that p62 was upregulat-
ed in the optic nerve after intravitreal injection of TNF, and
that this increase was completely inhibited by brimonidine.
Treatment with brimonidine alone also significantly decreased
p62 protein levels in the optic nerve compared with the basal
level.
Conclusions These results suggest that the modulation of p62
levels in the optic nerve by brimonidine may be involved
partly in its axonal protection.
Keywords p62 . Brimonidine . Autophagy . Tumor necrosis
factor . Optic nerve
Introduction
Brimonidine is a α2-adrenoreceptor agonist that lowers the
intraocular pressure (IOP) and is widely used for glaucoma
treatment. Several studies demonstrated that brimonidine has
a neuroprotective effect on retinal ganglion cells (RGCs). For
example, brimonidine protected RGCs in an in vivo transgen-
ic model of excessive oxidative stress [1] and protected RGCs
against ischemia [2, 3]. It was shown that intravitreal injection
of brimonidine upregulated brain-derived neurotrophic factor
(BDNF) expression in the rat retina [4]. Other reports also
demonstrated that brimonidine increased BDNF and p-AKT
expression and protected RGCs in the ocular hypertensive rat
retina [5]. Moreover, brimonidine inhibited the increases in
the expression of mitochondrial transcription factor A and
oxidative phosphorylation complex in the ischemic retina
[6]. Those studies focused on RGC body protection, and the
role brimonidine plays in their axons remains to be examined.
The p62, also called sequestosome 1 (SQSTM1), plays cru-
cial roles in the autophagy machinery, and its accumulation has
been linked to neurodegenerative disease [7–9]. Upregulated
p62 was found in the compressed spinal cord, and the forced
expression of p62 decreased the number of neuronal cells under
hypoxic stress [10]. It was demonstrated that the overexpres-
sion of p62 promotes apoptosis with the activation of caspase-
8, while knockdown of p62 reduces human glioma cell death
[11]. We previously found that there was a substantial increase
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in p62 protein levels in optic nerve samples 1 week after IOP
elevation in a rat hypertensive glaucoma model [12]. More
recently, we have demonstrated that there was also an increase
in p62 protein levels in the optic nerve after intravitreal injec-
tion of tumor necrosis factor (TNF) and that inhibition of p62
resulted in axonal protection in the optic nerve [13]. The TNF is
involved in certain types of glaucoma [14–19], and the TNF
injection model may be useful in understanding the mechanism
of axonal degeneration of RGCs [20]. In the present study, we
attempted to determine whether brimonidine modulates axonal
loss in TNF-induced optic nerve degeneration and affects the
expression of p62 in the optic nerve.
Materials and methods
Animals
Experiments were performed on 50- to 55-day-old male
Wistar rats; 44 rats and 22 rats were used for the immunoblot
analysis and axon counting studies, respectively. All studies
were conducted according to the Association for Research in
Vision and Ophthalmology (ARVO) statement for the Use of
Animals in Ophthalmic and Vision Research and were ap-
proved by the Ethics Committee of the Institute of
Experimental Animals of St. Marianna University Graduate
School of Medicine. The animals were housed in controlled
conditions, with temperature at 23±1 °C, humidity at 55±
5 %, and light from 06:00 to 18:00.
Administration of TNF
Intravitreal injection of TNF (Sigma-Aldrich, St. Louis, MO,
USA) was performed as described previously [20, 21].
Briefly, rats were anesthetized with an intramuscular injection
of a mixture of ketamine-xylazine (10 and 4 mg/kg, respec-
tively). A single 2-μl injection of 10 ng of TNF in 0.01 M
PBS, pH 7.40, was administered intravitreally into the right
eye of an animal under a microscope to avoid lens injury. The
PBS alone was administered into the contralateral left eye as a
control. In the brimonidine treatment groups, 2, 20, or
200 pmol of brimonidine tartrate (Senju Pharmaceutical Co.,
Ltd., Osaka, JAPAN) in 0.01M PBS was mixed with 10 ng of
TNF and administered intravitreally in a simultaneous injec-
tion. A previous study used a single 5-μl intravitreal injection
of brimonidine (0.85 μM to 34 μM, i.e., 4.25 pmol to
170 pmol) in rats and showed the upregulation of BDNF in
RGCs [4]. Therefore, our current brimonidine dosage (2-μl
intravitreal injection of 1 μM to 100 μM) is likely to be a
similar concentration. The rats were euthanized 1 or 2 weeks
after the intravitreal injections with an intraperitoneal over-
dose of sodium pentobarbital, followed by enucleation of the
eyes.
Immunoblot analysis
Forty-four rats were used for immunoblot analysis as de-
scribed previously [22]. Briefly, 1 or 2 weeks after intravitreal
injection, optic nerves (4 mm in length starting immediately
behind the globe) were collected, homogenized, and then cen-
trifuged at 15,000×g for 15 min at 4 °C. Two optic nerve
specimens were pooled into one sample, e.g., n=5 included
ten independent optic nerve samples per group. Protein con-
centrations were determined using the Bio-Rad Protein Assay
kit (Bio-Rad, Hercules, CA, USA). Protein samples (5 μg per
lane) were subjected to SDS-PAGE on gels (Bio-Rad) and
transferred to PVDF membranes (Immobilon-P, Millipore,
Billerica, MA, USA). Membranes were blocked with Tris-
buffered saline (TBS)-0.1 % Tween-20 containing 5 % skim
milk. Membranes were first reacted with anti-p62 antibody
(1:200; Medical & Biological Laboratories Co., Nagoya,
Japan) or anti-β-actin antibody (1:500; Sigma-Aldrich) in
TBS containing 5 % skim milk. Membranes were then se-
quentially exposed to peroxidase-labeled anti-rabbit IgG anti-
body (Cappel, Solon, OH, USA) or peroxidase-labeled anti-
mouse IgG antibody (Cappel) diluted 1:5000 in Tween-20 in
TBS. Western blots were visualized with an ECL detection
system (Amersham ECL Prime Western Blotting Detection
Reagents, GE Healthcare, Buckinghamshire, UK).
Axon counting in optic nerves
Morphometric analysis of each optic nerve was performed as
described previously with samples from 22 rats [20–22]. Eyes
were obtained from the animals 2 weeks after intravitreal in-
jection. Four-millimeter segments of the optic nerves were
obtained starting 1 mm behind the globe. These segments of
optic nerve were fixed by immersion in Karnovsky’s solution
for 24 h at 4 °C, processed, and embedded in acrylic resin.
Cross sections (1μm thick) were cut beginning 1mm from the
globe and stained with a solution of 1 % paraphenylene-
diamine (Sigma-Aldrich) in absolute methanol. For each sec-
tion, images at the center and at each quadrant of the periphery
(approximately 141.4 μm from the center) were acquired with
a light microscope (BX51; Olympus, Tokyo, JAPAN) with a
100× coupled digital camera (MP5Mc/OL; Olympus) and as-
sociated QCapture Pro software (version 5.1, QImaging,
Surrey, Canada). The acquired images were quantified using
Aphelion image-processing software (version 3.2, ADCIS SA
and AAI, Inc., Hérouville Saint Clair, France). The number of
axons was determined in five distinct areas of 1446.5 μm2
each (each quadrant of the periphery in addition to the center;
total area of 7232.3 μm2 per eye) from each eye. The number
of axons per eye was averaged and expressed as the number
per square millimeter. Aminimum of five eyes per experimen-
tal condition was used for analysis.
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Statistical analysis
Data are presented as mean ± SEM. Differences among
groups were analyzed using one-way ANOVA, followed by
the Mann–Whitney test. A probability value of less than 0.05
was considered to represent a statistically significant
difference.
Results
Effects of brimonidine on TNF-induced axonal
degeneration
We previously demonstrated that after an approximately 30 %
loss of axons 2 weeks after TNF injection, there was no further
loss of axons at 1 or 2 months [20]. In the present study,
compared with PBS-treated eyes (Fig. 1a), we confirmed sub-
stantial degenerative changes in the axons 2 weeks after TNF
injection (Fig. 1b), which were consistent with the findings of
our previous studies [20–22]. Brimonidine 20 pmol-treated
eyes showed apparent attenuated effects with better-
preserved nerve fibers (Fig. 1c). Substantial protective effects
on axons against TNF-induced optic nerve degeneration were
also seen in brimonidine 200 pmol-treated eyes (Fig. 1d).
Quantitative analysis showed that treatment with brimonidine
2 pmol tended to be modestly protective, but this was not
statistically significant (n=4; p=0.1859 versus TNF injection;
Fig. 1e). Treatment with brimonidine 20 pmol exerted a sig-
nificant protective effect against TNF-induced axonal loss (n=
4; p=0.00815 versus TNF injection; Fig. 1e). Brimonidine
200 pmol-treated eyes showed 86.4 % axonal protection com-
pared with eyes after TNF injection alone (n=7; p=0.00601
versus TNF injection; Fig. 1e).
Fig. 1 Brimonidine prevented
TNF-induced axon loss. Light
microscopic findings 2 weeks
after (a) PBS injection, (b) 10-ng
TNF injection, (c) 10-ng TNF+
20-nmol brimonidine injection, or
(d) 10-ng TNF +200-nmol
brimonidine injection. Scale
bar=10 μm (a–d). (e) Effect of
brimonidine (2–200 nmol) on
axon numbers in the optic nerve.
Each column represents
mean±SEM; n=4–7 per group.
*p<0.05; **p<0.005
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Effects of brimonidine on p62 protein levels in optic nerves
We previously found that p62 was increased in optic nerve
samples 1 week after TNF injection [13] at the time before
axon loss became obvious. In the current study, we examined
the effect of brimonidine on p62 protein levels 1 and 2 weeks
after intravitreal injection, and the latter time point is when
axon loss becomes obvious [20]. Consistent with our previous
results [13], there was a significant increase in p62 protein
levels in the optic nerve samples 1 week after TNF injection
(Fig. 2a–c). This increase was completely abolished by
brimonidine (Fig. 2a–c). Moreover, treatment with
brimonidine alone significantly decreased p62 protein levels
in the optic nerve compared with the basal level (Fig. 2d).
Furthermore, there was a tendency for p62 protein levels to
increase in the optic nerve samples 2 weeks after TNF injec-
tion, but this was not statistically significant (n=4; p=
0.083265 versus PBS injection; Fig. 2e). However, this in-
crease was completely abolished by brimonidine (Fig. 2e).
Discussion
In the present study, brimonidine exerted a substantial protec-
tive effect against axonal loss after TNF injection. Axonal
protection by brimonidine was also seen in different optic
nerve injury models. For example, pretreatment with
brimonidine significantly reduced axonal loss in an ischemic
optic neuropathy model [23]. This is consistent with the re-
sults of a previous study showing that systemic brimonidine,
which did not affect IOP, exerted substantial axonal protection
following ocular hypertension [24]. That study found that sys-
temic brimonidine ameliorated anterograde transport deficits
due to ocular hypertension [24]. Thus, it is possible that the
protective effects of brimonidine are associated with its im-
provement of anterograde and retrograde transport [25, 26]. In
addition to axonal protection, axonal regeneration by
brimonidine was reported. It was shown that treatment with
brimonidine resulted in enhanced axonal growth in juvenile,
glaucomatous, and optic nerve crush retinas in vitro [27]. A
Fig. 2 p62 protein levels in optic
nerves. Immunoblot data are
normalized toβ-actin levels in the
same sample. a Immunoblotting
for p62 1 week after PBS
injection, 10-ng TNF injection, or
10-ng TNF + 200-nmol
brimonidine injection. b
Immunoblotting for β-actin in the
same sample. c Data are
expressed as percentage of
control. Each column represents
mean ± SEM. n=5 (10 optic
nerves) per group. *p<0.05. d
Immunoblotting for p62 1 week
after PBS injection or 200-nmol
brimonidine injection. Data are
expressed as percentage of
control. Each column represents
mean ± SEM. n=eight (8 optic
nerves) per group. *p<0.05. e
Immunoblotting for p62 2 weeks
after PBS injection, 10-ng TNF
injection, or 10-ng TNF + 200-
nmol brimonidine injection. Data
are expressed as percentage of
control. Each column represents
mean ± SEM. n=eight (8 optic
nerves) per group. *p<0.05
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recent in vivo study has determined that Erk1/2 activity is
required for brimonidine-mediated axonal regeneration after
optic nerve injury [28]. Thus, it is likely that brimonidine has
beneficial effects on axonal protection as well as axonal re-
generation in several distinct types of optic nerve damage.
A constitutively high level of p62 under pathological
conditions leads to the accumulation of damaged mito-
chondria and subsequent reactive oxygen species pro-
duction [29], and the accumulation of p62 after autoph-
agy inhibition causes a delay in the clearance of short-
lived ubiquitin-proteasome system-specific substrates,
like p53, which may mediate toxicity [30]. In the pres-
ent study, we observed an increase in the p62 protein
level in the optic nerve after TNF injection, consistent
with the results of our previous study [13], and this
increase was completely inhibited by the simultaneous
injection of brimonidine. It is interesting to note that
autophagosome formation was increased in response to
β2-agonist administration in rat skeletal muscle [31].
Augmented formation of autophagosomes was also ob-
served in the K562 cell line following α1-agonist treat-
ment [32]. Therefore, it is reasonable to speculate that
adrenoceptor stimulation may affect autophagy machin-
ery, although further studies will be needed to clarify
the involvement of α-adrenergic receptor regulation
within the optic nerve. Because p62 accumulates when
autophagy is inhibited, and decreased levels can be ob-
served when autophagy is induced, p62 may be used as
a marker of autophagy flux [33]. It was shown that β-
adrenoceptor stimulation enhanced autophagic flux by
promoting lysosomal degradation in fat cells [34]. It
was also reported that norepinephrine strongly enhances
autophagic flux in cultured cardiac fibroblasts [35]. The
level of p62 may be dependent on the balance between
the incoming flux, which is the transcriptional regula-
tion in response to various stimuli, and outgoing flux,
which is influenced by autophagic activity [36]. Since
we found that brimonidine decreased p62 levels in the
optic nerve compared with the basal level, one hypoth-
esis posits that this may be because brimonidine directly
affects p62 expression, such as by increasing autophagic
flux, rather than indirectly exerting effects resulting
from axonal protection. Taking the various results to-
gether, it is possible that brimonidine exerts axonal pro-
tection with the involvement of autophagy machinery.
In conclusion, the present study showed that the modula-
tion of p62 levels by brimonidine in the optic nerve might be
involved in part in its axonal protective effects. Further studies
are needed to clarify the mechanism by which brimonidine
alters p62 expression.
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